Management of toxicities from antibody – drug conjugates in breast cancer - Takeaways - MDSpire

Management of toxicities from antibody – drug conjugates in breast cancer

  • By

  • Ajay Gogia

  • May 29, 2026

  • 0 min

Share

  • 1

    Antibody-drug conjugates (ADCs) have significantly advanced breast cancer treatment by delivering targeted cytotoxic agents.

  • 2

    The review synthesizes clinical and real-world data to create a framework for managing toxicities associated with ADCs.

  • 3

    Distinct toxicity profiles of ADCs are influenced by factors such as payload, linker stability, and antigen expression.

  • 4

    Proposed algorithms aim to manage adverse events across various organ systems, including pulmonary and gastrointestinal effects.

  • 5

    The review highlights the need for coordinated, multidisciplinary approaches to enhance safety and adherence in ADC treatment.

Original Source(s)

Management of toxicities from antibody – drug conjugates in breast cancer

  • by Ajay Gogia

  • May 29, 2026

Related Content

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma